Merck KGaA Stock Forecast for 2023 - 2025 - 2030
Updated on 03/29/2024
Merck KGaA Stock Forecast and Price Target
Based on the current earnings figures, this year's price targets for Merck KGaA were recently set by four distinguished experts, with an average mark of 172.00€. If it reached this goal, it would represent a potential upside of approximately 9.73% from the previous closing price in March, 2024. The high end is 200.00€, and the low is 155.00€. If you are interested in MRK stock, it is important to also consider its competitors.
9.73% Upside
Merck KGaA Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Merck KGaA's Price has decreased by 100.00%, going from 125.36€ to 0.00€. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach 174.00€ – an increase of 100.00%. The Merck KGaA forecast is for Fair Value to reach 287.01€ or grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$734.37 | Buy/Sell | $636.99 | 10.71% |
AVGO Stock Forecast | Broadcom | Outperform |
8
|
$1.29k | Buy/Sell | $1.21k | 20.64% |
NOVO B Stock Forecast | Novo Nordisk A/S | Outperform |
12
|
kr895.10 | Buy/Sell | kr696.07 | 6.13% |
JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$161.23 | Buy/Sell | $174.55 | 5.44% |
ABBV Stock Forecast | AbbVie | Outperform |
9
|
$179.63 | Buy/Sell | $178.42 | 0.21% |
Merck KGaA Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Merck KGaA's Revenue has increased by 26.79%, going from 17.53€B to 22.23€B. 15 analysts predict Merck KGaA's Revenue will decrease by 0.46% in the next year, reaching 22.13€B. The Merck KGaA forecast is for Revenue to reach 30.94€B or grow by 39.16%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
MRK Stock Forecast | Merck | Outperform |
2
|
$122.77 | Buy/Sell | $130.51 | 9.96% |
ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$120.19 | Buy/Sell | $118.92 | 4.83% |
AZN Stock Forecast | AstraZeneca PLC | Outperform |
17
|
£104.50 | Buy/Sell | £165.99 | 53.79% |
Merck KGaA Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Merck KGaA's Dividend per Share has grown, increasing from 1.40€ to 2.20€ – an increase of 57.14%. For next year, the 14 analysts predict Dividend per Share of 2.29€, which would mean an increase of 4.09%. Over the next seven years, the pros' prediction is Dividend per Shareof 3.37€, which would mean a seven-year growth forecast of 53.18%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
NOVN Stock Forecast | Novartis | Outperform |
10
|
CHF88.80 | Buy/Sell | CHF105.00 | 23.95% |
DHR Stock Forecast | Danaher | Outperform |
10
|
$252.80 | Buy/Sell | $260.33 | 2.85% |
GE Stock Forecast | General Electric | Outperform |
8
|
$166.56 | Buy/Sell | $144.00 | 6.27% |
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AMGN Stock Forecast | Amgen | Outperform |
4
|
$275.36 | Buy/Sell | $303.65 | 14.40% |
MDT Stock Forecast | Medtronic | Outperform |
11
|
$85.50 | Buy/Sell | $92.47 | 11.11% |
BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$54.36 | Buy/Sell | $58.15 | 1.18% |
Merck KGaA EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Merck KGaA's EBITDA has grown, increasing from 4.60€B to 6.56€B – a growth of 42.55%. The next year, 12 experts forecast that Merck KGaA's EBITDA will decrease by 5.16%, reaching 6.22€B. Over the next seven years, experts anticipate that Merck KGaA's EBITDA will grow at a rate of 43.88%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
AI Stock Forecast | L'Air Liquide | Outperform |
17
|
192.84€ | Buy/Sell | 178.09€ | -0.69% |
GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$75.32 | Buy/Sell | $87.82 | 10.20% |
GSK Stock Forecast | GSK | Outperform |
12
|
£16.75 | Buy/Sell | £17.30 | 11.04% |
Merck KGaA EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Merck KGaA's EBIT has grown by 62.78%, from 3.08€B to 5.01€B. According to the 12 analysts polled, in the next year, Merck KGaA's EBIT will fall by 13.20%, reaching 4.35€B. Over the next seven years, experts predict that EBIT will grow by 49.02%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$239.50 | Buy/Sell | $284.47 | 16.91% |
PH Stock Forecast | Parker-Hannifin Corp | Outperform |
10
|
$536.04 | Buy/Sell | $548.76 | 7.10% |
ECL Stock Forecast | Ecolab | Hold |
18
|
$223.90 | Buy/Sell | $205.36 | 1.38% |
Merck KGaA EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Merck KGaA's EPS has decreased by 100.00%, going from 6.70€ to 0.00€. In the next year, analysts are expecting an increase in EPS, predicting it will reach 9.30€ – an increase of 100.00%. The Merck KGaA forecast is for EPS to reach 15.34€ or grow by 100.00%.
Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
---|---|---|---|---|---|---|---|
4568 Stock Forecast | Daiichi Sankyo Company | Buy |
4
|
¥4.83k | Buy/Sell | ¥5.24k | 18.04% |
APD Stock Forecast | Air Products and Chemicals | Outperform |
16
|
$247.94 | Buy/Sell | $310.73 | 6.48% |
MMM Stock Forecast | 3M | Hold |
10
|
$94.05 | Buy/Sell | $109.39 | 15.90% |